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Abstract
Background: Zambia was the first African country to change national antimalarial treatment policy to artemisinin-based
combination therapy – artemether-lumefantrine. An evaluation during the early implementation phase revealed low
readiness of health facilities and health workers to deliver artemether-lumefantrine, and worryingly suboptimal treatment
practices. Improvements in the case-management of uncomplicated malaria two years after the initial evaluation and
three years after the change of policy in Zambia are reported.
Methods: Data collected during the health facility surveys undertaken in 2004 and 2006 at all outpatient departments
of government and mission facilities in four Zambian districts were analysed. The surveys were cross-sectional, using a
range of quality of care assessment methods. The main outcome measures were changes in health facility and health
worker readiness to deliver artemether-lumefantrine, and changes in case-management practices for children below five
years of age presenting with uncomplicated malaria as defined by national guidelines.
Results: In 2004, 94 health facilities, 103 health workers and 944 consultations for children with uncomplicated malaria
were evaluated. In 2006, 104 facilities, 135 health workers and 1125 consultations were evaluated using the same criteria
of selection. Health facility and health worker readiness improved from 2004 to 2006: availability of artemether-
lumefantrine from 51% (48/94) to 60% (62/104), presence of artemether-lumefantrine dosage wall charts from 20% (19/
94) to 75% (78/104), possession of guidelines from 58% (60/103) to 92% (124/135), and provision of in-service training
from 25% (26/103) to 41% (55/135). The proportions of children with uncomplicated malaria treated with artemether-
lumefantrine also increased from 2004 to 2006: from 1% (6/527) to 27% (149/552) in children weighing 5 to 9 kg, and
from 11% (42/394) to 42% (231/547) in children weighing 10 kg or more. In both weight groups and both years, 22%
(441/2020) of children with uncomplicated malaria were not prescribed any antimalarial drug.
Conclusion: Although significant improvements in malaria case-management have occurred over two years in Zambia,
the quality of treatment provided at the point of care is not yet optimal. Strengthening weak health systems and improving
the delivery of effective interventions should remain high priority in all countries implementing new treatment policies
for malaria.
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Background
By June 2006, 39 African countries had changed their pol-
icies to recommend artemisinin-based combination ther-
apy (ACT) as the first line treatment for malaria [1] to
reduce the devastating effects of failing monotherapies [2]
and limit the spread of drug resistance [3]. This represents
one of the most significant public health developments in
malaria control for decades. To implement these policies,
several key challenges remain: increasing sustainable
financing of these expensive treatments, improving
prompt access through better care-seeking at health facili-
ties and high quality community-based delivery systems,
and ensuring these new drugs are used appropriately dur-
ing clinical management.
Of these challenges, inadequate case-management prac-
tices are of particular concern. In health facilities across
Africa, febrile children are often treated suboptimally [4-
7], incorrect doses of antimalarials are frequently pre-
scribed [8-10], and appropriate counseling and drug dis-
pensing is rarely provided [10-12]. Therefore, the
introduction of ACTs, which are new, expensive and more
complex antimalarial regimens with less well described
safety profiles poses, both a challenge and an opportunity
to the quality of malaria management in Africa.
In 2002, due to chloroquine resistance [13-15], Zambia
became one of the first countries in Africa to change its
treatment policy for uncomplicated malaria from chloro-
quine to ACT: artemether-lumefantrine for children and
non-pregnant adults weighing 10 kg or more and sul-
phadoxine-pyrimethamine for children less than 10 kg
[16]. The Zambian Government, with support from exter-
nal funding partners, made substantial progress in 2003
and 2004 to secure adequate drug supplies, conduct in-
service training for health workers, and revise clinical
guidelines and wall charts [16].
Health workers' performance in treating febrile paediatric
patients at government clinics in Zambia was reported
when the new drug policy was in its nascent implementa-
tion phase [17]. Here, a follow-up study was presented to
evaluate how febrile children are managed with arte-
mether-lumefantrine approximately two years after the
initial survey.
Methods
Study sites and timing
The survey was undertaken in four districts purposively
selected to represent major malaria ecologies in Zambia:
Chingola, Kalomo, Chipata and Samfya [17]. All govern-
ment and mission health facilities providing outpatient
care were surveyed between January and March 2004 to
assess the quality of malaria case-management, three to
11 months following the implementation of the new arte-
mether-lumefantrine drug policy. Between March and
May 2006, a follow-up survey was undertaken at all facil-
ities in the same districts. Ethical approval was provided
by the Boston University IRB (2003-412B and H-25346)
and Research Ethics Committee of the University of Zam-
bia (Federal Wide Assurance Number IRB00001131 and
IRB00000338).
Survey design and data collection
The quality of antimalarial prescriptions, counseling and
drug dispensing was studied using a cross sectional, clus-
ter sample survey at all health facilities in four districts
using similar methods in both the 2004 and 2006 surveys.
A cluster was defined as all sick outpatients seen at a
health facility during one working day. Each facility was
randomly assigned to one survey day and all patients pre-
senting to outpatient departments during the survey day
were recruited. Here, case-management practices in chil-
dren below five years of age were described, while data on
patients five years and above will be presented elsewhere.
Data were collected by four teams, each composed of two
surveyors, using three methods: 1) exit interviews with
caretakers, 2) health worker interviews, and 3) health
facility assessments. Prior to the interviews, all caretakers
and health workers were asked to provide written
informed consent. For exit interviews, all caretakers of sick
children were interviewed when they completed the
health facility visit. Interviewers asked questions about
the child's age, history of fever during the present illness,
use of antimalarial drugs prior to the facility visit, and if
the visit was an initial or follow-up consultation. Informa-
tion was also collected from patient held records about
routine diagnostic procedures requested and results
reported, medications prescribed, and if the child was
treated as an outpatient or referred for hospitalisation. For
prescribed antimalarial drugs, interviewers assessed if the
drug was dispensed, whether swallowing of the first dose
was observed at the health facility, and if the caretaker
received instructions on how to give the drugs at home.
This information was obtained from caretaker interviews
and referred not only to the consultation but also to any
time during the facility visit. Finally, during the exit inter-
view, each child was weighed and the axillary temperature
was measured.
Health worker interviews were conducted after working
hours with all health workers who had attended sick chil-
dren during the survey day. Health workers were asked
about their demographics, pre-service training, working
experience, supervisory visits, possession of guidelines,
and exposure to in-service case-management trainings.
Health workers' knowledge about recommended first-line
treatment for various patient groups with uncomplicated
malaria was assessed using open-ended questions.Malaria Journal 2007, 6:31 http://www.malariajournal.com/content/6/1/31
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Finally, a health facility assessment was performed to
record the availability of medical supplies and equipment
related to malaria case-management. The presence of
weighing scales, thermometers, malaria treatment wall
charts and malaria diagnostics (microscopy and rapid
diagnostic tests) was assessed. Particular emphasis was
paid to the availability of antimalarial drugs on the day of
the survey and stock-out periods in the past 12 months.
Definitions
Diagnosis definitions reflected recommendations from
Zambian national guidelines [18,19] and training manu-
als used during in-service training for health workers on
malaria case-management [20,21]. According to these ref-
erence materials, any child with fever or history of fever in
the absence of signs of severe malaria was presumed to
have uncomplicated malaria in high malaria risk areas.
For clinical management purposes, all Zambia is consid-
ered as a high malaria risk area and the presence of fever
in children irrespective of other signs provides enough
evidence to suspect malaria [19-21]. A case of uncompli-
cated malaria was defined as a child below five years of
age who presented to a health facility for an initial visit
with a history of fever during the present illness or an axil-
lary temperature of 37.5°C or more, and who was treated
as an outpatient in the absence of a negative malaria test.
Ambiguities exist regarding the role of malaria diagnostics
in malaria case-management. The national malaria guide-
line states that the "presence of signs and symptoms of
disease with negative blood smear does not preclude the
diagnosis of malaria" [18] and similar ambiguous recom-
mendations appear in training manuals [20,21]. Regard-
ing the interpretation of rapid diagnostic tests, none of the
reference materials provides instructions on how health
workers should act upon negative results. To prevent
health worker practices from being judged as incorrect
due to ambiguity, children with a negative malaria test
were excluded from the analysis.
Recommended treatment for uncomplicated malaria was
defined according to national guidelines and training
materials: artemether-lumefantrine for children weighing
10 kg or more and sulphadoxine-pyrimethamine for chil-
dren less than 10 kg [18-23]. Further ambiguities that
were subsequently identified in the latter recommenda-
tion are described in the results.
Data entry and statistical analysis
Data were double-entered and verified in Microsoft Access
and used STATA 8 (StataCorp, College Station, Texas) for
statistical analysis. Descriptive analysis was undertaken at
health facility, health worker and child level. At health
facility and health worker level chi-square test was used to
test significant differences in proportions between 2004
and 2006 surveys. At child level the precision of propor-
tions (95% confidence interval) was estimated accounting
for the cluster sampling design using "health facility-day"
as the primary sampling unit. Hypothesis testing and con-
fidence interval estimation were done with an alpha level
of 0.05.
Results
Changes in health facility and health worker readiness to 
deliver artemether-lumefantrine
There were 94 facilities assessed in 2004 and 104 in 2006
(table 1). The distribution of health facility types was sim-
ilar between the two surveys. The presence of thermome-
ters and weighing scales was generally high in both survey
rounds. However in June 2005 the introduction of
malaria rapid diagnostic tests into the facilities greatly
increased parasitological diagnostic capacity, from 17%
(16/94) in 2004 based solely on microscopy to 73% (76/
104) (P < 0.001) in 2006 largely relying on rapid diagnos-
tic tests. The widespread distribution of revised arte-
mether-lumefantrine dosing wall charts from November
2005 also greatly increased the availability of these job
aides, from 20% (19/94) in 2004 to 75% (78/104) (P <
0.001) in 2006.
Chloroquine had been successfully removed from the
health facilities by 2006 (table 1). Sulphadoxine-
pyrimethamine was widely available in 2004 and 2006.
Artemether-lumefantrine was available at 60% (62/104)
of the facilities surveyed in 2006, a slight, though statisti-
cally not significant improvement over 2004 (51%, 48/
94) (P = 0.227). During the 2006 survey, 12 facilities had
incomplete stock-out documentation over the preceding
12 months. Among the remaining 92 facilities, arte-
mether-lumefantrine stock-outs were common; on aver-
age health facilities experienced stock-outs of the different
dose pack sizes ranging between 108 and 123 days. Seven
percent (7/104) of facilities had expired stocks of arte-
mether-lumefantrine.
A variety of in-service training activities had been under-
taken since the launch of the new artemether-lumefan-
trine drug policy in Zambia and after the 2004 survey.
Notably these included a national malaria training course
sponsored by Novartis Pharma Ltd, provincial and district
level trainings organized by the National Malaria Control
Centre and the Integrated Management of Childhood Ill-
nesses (IMCI) programme in Zambia began to train
health workers on the use of artemether-lumefantrine.
The proportion of health workers receiving any form of
training that included artemether-lumefantrine rose from
25% (26/103) in 2004 to 41% (55/135) two years later (P
< 0.001) (Table 1).Malaria Journal 2007, 6:31 http://www.malariajournal.com/content/6/1/31
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During the 2004 survey 58% (60/103) of health workers
had been provided with a draft version of new national
guideline on malaria case-management. These guidelines
were officially printed and distributed to health workers
from August 2004 [18]. Furthermore, new treatment rec-
ommendations for malaria have been gradually incorpo-
rated into IMCI guidelines [19], Integrated Technical
Guidelines for Front Line Health Workers [22] and Stand-
ard Treatment Guidelines [23]. In 2006, the proportion of
health workers who had in their possession at least one
guideline that recommended use of artemether-lumefan-
trine rose to 92% (124/135) (P < 0.001). Similar propor-
Table 1: Characteristics of health facilities and health workers during 2004 and 2006 surveys in Zambia
2004 2006
Health facility characteristics N = 94 N = 104
No (%) No (%)
Type of facility
Hospital-affiliated health center 7 (7.4) 6 (5.8)
Urban health center 7 (7.4) 8 (7.7)
Rural health center 78 (83.0) 87 (83.7)
Health post 2 (2.1) 3 (2.9)
Equipment available at facility
Weighing scale 92 (97.9) 99 (97.1)*
Thermometer† 91 (97.8)‡ 90 (88.2)*
Working microscope 16 (17.0) 18 (17.3)
Malaria rapid diagnostic test† 0 65 (62.5)
Any test (malaria rapid diagnostic test or 
microscopy)†
16 (17.0) 76 (73.1)
Wall charts
Artemether-lumefantrine dosage chart† 19 (20.2) 78 (75.0)
Sulphadoxine-pyrimethamine dosage chart 48 (51.1) 39 (37.5)
Quinine dosage chart 4 (4.3) 4 (3.9)
Available drugs on the survey day
Artemether-lumefantrine (any non-expired 
tablets)
48 (51.1) 62 (59.6)
Sulphadoxine-pyrimethamine (any 
formulation)†
94 (100) 96 (92.3)
Quinine (injection) 68 (72.3) 78 (75.0)
Quinine (tablets) 74 (78.7) 90 (86.5)
Chloroquine (any formulation)† 71 (75.5) 0
Health worker characteristics N = 103 N = 135
No (%) No (%)
Pre-service training
Clinical officer 30 (29.1) 38 (28.2)§
Enrolled Nurse 49 (47.6) 52 (38.5)
Registered nurse 4 (3.9) 10 (7.4)
Other 20 (19.4) 35 (25.9)
In-service training including recommendations 
on the use of artemether-lumefantrine†
26 (25.2) 55 (40.7)
Possession of guidelines that included 
artemether-lumefantrine recommendations†
60 (58.3) 124 (91.9)
Frequency of supervision (past 6 months)
0 visit 14 (13.6) 16 (11.9)
1 visit† 22 (21.4) 56 (41.5)
2 visits 42 (40.8) 52 (38.5)
3 or more visits† 25 (24.3) 11 (8.1)
* Denominator does not include two observations with missing value
† P-value < 0.05 using chi-square test of significance
‡ Denominator does not include one observation with missing value
§ The clinical officer category includes one physicianMalaria Journal 2007, 6:31 http://www.malariajournal.com/content/6/1/31
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tions of health workers had received at least one
supervisory visit in the six months prior to both the 2004
(86%, 89/103) and 2006 (88%, 119/135) surveys. During
the six months preceding the 2006 survey, 71% (94/133;
two missing values) of health workers reported at least
one supervisory visit that included discussion on appro-
priate use of artemether-lumefantrine. Health workers'
knowledge on the recommended treatment for uncompli-
cated malaria was generally high for children weighing 10
kg and more (87%, 117/135), however 33% (44/135) of
health workers reported that artemether-lumefantrine was
recommended for children weighing less than 10 kg.
Changes in antimalarial treatment practices for children 
with uncomplicated malaria
During the 2006 survey, 1,498 children aged less than five
years were evaluated as they left the clinic with their care-
takers and were not referred for hospitalization. Four chil-
dren were excluded from analysis because data were
incomplete. Further 369 children were excluded because
they presented for follow-up visit, had neither history of
fever nor an axillary temperature of 37.5°C or more, or
had a negative parasitological test. The influence of diag-
nostics on malaria diagnosis and treatment will be pre-
sented elsewhere. The remaining 1,125 children fulfilled
our definition of uncomplicated malaria. Of these 1,125
children, 26 children weighed less than 5 kg, 552 were
between 5 and 9 kg and 547 were 10 kg or more; compa-
rable numbers of children were evaluated following the
same selection criteria in 2004 (23, 527, and 394, respec-
tively).
In 2004, during the early implementation of the treat-
ment policy, artemether-lumefantrine was not recom-
mended for children less than 10 kg; they were supposed
to be treated with sulphadoxine-pyrimethamine. In Octo-
ber 2005, the Zambian Central Board of Health officially
recommended the use of artemether-lumefantrine in
patients weighing 5 to 9 kg [24]; and from November
2005, revised wall charts were distributed to health facili-
ties that recommended that children weighing between 5
to 9 kg should be treated with six tablets of artemether-
lumefantrine over three days. Given this discrepancy
between the guidelines, primary analysis included only
patients fulfilling our inclusion criteria who weighed 5 kg
and more during both the 2004 and 2006 surveys and
results are presented for children weighing 5 to 9 kg, and
10 kg or more separately. Of the 23 patients weighing less
than 5 kg in 2004, six were not provided with an antima-
larial, and 17 were prescribed sulphadoxine-pyrimeth-
amine. In 2006, of the 26 patients weighing less than 5 kg,
14 did not receive an antimalarial, 10 received sulphadox-
ine-pyrimethamine and two were prescribed artemether-
lumefantrine.
The treatment quality was first examined at all health
facilities surveyed in 2004 and 2006, whether or not they
had artemether-lumefantrine in stock (Table 2). In 2004,
children with uncomplicated malaria weighing 5 to 9 kg
were predominantly prescribed sulphadoxine-pyrimeth-
amine (80%, 422/527), and only six children (1%)
received artemether-lumefantrine. In 2006, more children
in the same weight group were treated with artemether-
lumefantrine (27%, 149/552), and 39% received sul-
phadoxine-pyrimethamine. Among children 10 kg or
more, for whom the wall charts and guidelines are less
ambiguous, the proportion of children receiving arte-
mether-lumefantrine increased significantly from 11%
(42/394) in 2004 to 42% (231/547) in 2006 (table 2).
Many children with uncomplicated malaria left clinics
without any antimalarial prescribed: 22% (441/2020)
across both weight groups and both years (Table 2). In
74% (327/441) of these children, a diagnosis of unspeci-
fied respiratory tract infection (30%, 131/441), pneumo-
nia (16%, 70/441), eye infection (15%, 68/441),
diarrhoeal disease (12%, 52/441), skin infection (11%,
50/441) or ear infection (3%, 14/441) was recorded. Con-
versely, only 34% (534/1579) of children having an anti-
malarial drug prescribed had any of these diagnoses
recorded.
Of particular interest during the 2004 survey was the
observation that only 22% (42/192) of children with
uncomplicated malaria weighing 10 kg or more who pre-
sented to a facility where artemether-lumefantrine was in
stock on the day of the survey received artemether-lume-
fantrine and 54% (103/192) of these children were pre-
scribed sulphadoxine-pyrimethamine (table 3). Two years
later the proportion of children prescribed artemether-
lumefantrine rose significantly to 59% (219/374). This
was also true for the increase in artemether-lumefantrine
prescriptions for children weighing 5 to 9 kg, which rose
from 2% (6/254) in 2004 to 41% (144/351) in 2006. An
important proportion (26%, 309/1,171) of children of
any weight group in both years still left these clinics where
artemether-lumefantrine was in stock without any anti-
malarial (Table 3).
Artemether-lumefantrine dosage, drug dispensing, and 
counselling
The correctness of prescribed artemether-lumefantrine
dosages was assessed according to weight-specific criteria.
The correctness was very high (81% to 96%) in all weight
groups, except for children 15–24 kg because they tended
to receive dosages designed for a lower weight category
(table 4). Of the 48 children having artemether-lumefan-
trine dispensed in 2004, 21 (44%) had their first dose
administered at the facility, all under observation of
health workers. In 2006, 58% (206/354) were given theMalaria Journal 2007, 6:31 http://www.malariajournal.com/content/6/1/31
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first dose at the facility and nearly all (97%, 200/206) had
swallowing of the first dose observed. All 48 caretakers
were provided advice on the dosing schedule of arte-
mether-lumefantrine in 2004 as were 98% (347/355) in
2006. Advice to take artemether-lumefantrine after the
meal was provided to only 31% (15/48) of caretakers in
2004 but this rose to 71% (251/355) in 2006.
Discussion
Improvements in implementing artemether-lumefantrine 
policy
Programmatic activities improved the readiness of health
facilities and health workers to deliver artemether-lume-
fantrine to febrile children between 2004 and 2006. Facil-
ities with trained staff, guidelines and wall charts
developed around the new drug policy had increased two
years following the early implementation survey (Table
1). At facilities where artemether-lumefantrine was in
stock, the proportions of children weighing 10 kg or
more, who should have received this drug, increased from
22% in 2004 to 59% in 2006 (Table 3). Although results
are not yet optimal, these are encouraging findings. How-
ever, they further demonstrate that the implementation of
new treatment policies is a long process where even sev-
eral years after the launch of the process further interven-
tions are still required. This is an important lesson for
other countries either starting to implement ACTs or
which opted for interim treatment strategies while await-
ing decisions on ACT policies.
Challenges facing optimum implementation of 
artemether-lumefantrine policy
There continue to be several important health system and
information dissemination problems that limit effective
implementation of the new drug policy. First, drug stock
management is probably a major rate-limiting step to
effective delivery of artemether-lumefantrine. In 2006,
40% of facilities still did not have any artemether-lume-
fantrine in stock on the survey day, facilities were out of
stock for approximately 30% of the year, and some (7%)
had expired drugs. Ensuring adequate supplies of arte-
mether-lumefantrine is a complex process in Zambia, crit-
ically dependent on the quantification of consumption
for each of four different dose packages, processing of
orders through districts to national stores, and subsequent
prompt distribution of adequate quantities to districts
and facilities. The effectiveness of the supply chain is fur-
ther complicated with international procurement of arte-
mether-lumefantrine, single source of the product and
potential shortages of the drug on the global market. Fur-
ther investigation of artemether-lumefantrine supply
chain and strengthening of the drug distribution is an
immediate priority in Zambia and probably in other
countries implementing ACTs in Africa [25].
Second, the implementation process of artemether-lume-
fantrine was launched in 2003 when there was little pub-
lished data and no international guidance, on the use of
this drug among patients weighing less than 10 kg. The
national guidelines therefore recommended that arte-
mether-lumefantrine be withheld from patient's weighing
less than 10 kg and that sulphadoxine-pyrimethamine
should be used in this weight group. This clearly posed
Table 2: Antimalarial treatments for children with uncomplicated malaria presenting to all health facilities – change of practice 
between 2004 and 2006 surveys in four districts in Zambia
2004 5–9 kg (N = 527) ≥ 10 kg (N = 394)
No (%) 95% CI* No (%) 95% CI*
Artemether-lumefantrine 6 (1.1) 0, 2.7 42 (10.7) 5.4, 16.0
Sulphadoxine-pyrimethamine 422 (80.1) 73.9, 86.2 266 (67.5) 58.8, 76.2
Quinine 14 (2.7) 0.8, 4.5 19 (4.8) 2.0, 7.6
Chloroquine 1 (0.2) 0, 0.6 0 NA
No antimalarial prescribed 84 (15.9) 10.3, 21.6 67 (17.0) 11.7, 22.3
2006 5–9 kg (N = 552) ≥ 10 kg (N = 547)
No (%) 95% CI* No (%) 95% CI*
Artemether-lumefantrine 149 (27.0) 19.2, 34.8 231 (42.2) 33.8, 50.7
Sulphadoxine-pyrimethamine 214 (38.8) 30.9, 46.7 151 (27.6) 19.9, 35.3
Quinine 26 (4.7) 1.5, 7.9 38 (7.0) 2.5, 11.4
No antimalarial prescribed 163 (29.5) 23.3, 35.8 127 (23.2) 17.9, 28.5
* Confidence intervals adjusted for cluster samplingMalaria Journal 2007, 6:31 http://www.malariajournal.com/content/6/1/31
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problems in Zambia, where there was evidence that sul-
phadoxine-pyrimethamine failure rates were already high
[14,26]. In June 2005, Falade and colleagues published
multi-site trial data among infants weighing 5 to 9 kg and
reported that artemether-lumefantrine was both safe and
efficacious in this patient group [27]. In October 2005,
the Zambian Central Board of Health made an important
decision to recommend artemether-lumefantrine in
patients with uncomplicated malaria weighing 5 to 9 kg.
This weight group recommendation is consistent with
those specified as part of national guidelines developed
during 2005 and 2006 in Kenya [28], Tanzania [29] and
Uganda [30]. Wall charts and notification to health facil-
ity staff in Zambia were disseminated with these revised
instructions toward the end of 2005. An inevitable conse-
quence of this change was that national formulary, IMCI
flowcharts and clinical guidelines revised between 2003
and 2005 around sulphadoxine-pyrimethamine recom-
mendations for children less than 10 kg now differed
from the latest recommendations. Furthermore, prior to
this recent revision, health workers have been trained to
use artemether-lumefantrine only in children 10 kg and
above. Consequently fewer children 5 to 9 kg in 2006 had
received this drug compared to children weighing 10 kg or
more (Tables 2 and 3).
The early introduction of new effective post-registration
drugs into public health use is important when current
therapies are failing to cure life threatening illnesses like
malaria. However, the results of trials in special groups
often emerge post-registration and national health offi-
cials need to respond to any changing recommendations.
Changing and implementing revisions to a major drug
policy, such as the treatment of malaria, is fraught with
financing, coordination and human resource problems
that can overwhelm the government agencies charged
Table 4: Correctness of artemether-lumefantrine dosage prescriptions – change of practice between 2004 and 2006 surveys in four 
districts in Zambia
Recommended No (%) Overdose No (%) Underdose No (%) Dose not specified No (%)
2004
All children 5–24 kg (N = 48) 39(81.3) 2 (4.2) 5 (10.4) 2 (4.2)
5–9 kg (N = 6) 5 (83.3) 1 (16.7) 0 0
10–14 kg (N = 34) 31 (91.2) 1 (2.9) 0 2 (5.9)
15–24 kg (N = 8) 3 (37.5) 0 5 (62.5) 0
2006
All children 5–24 kg (N = 380) 338 (89.0) 11 (2.9) 28 (7.4) 3 (0.8)
5–9 kg (N = 149) 143 (96.0) 0 5 (3.4) 1 (0.7)
10–14 kg (N = 185) 173 (93.5) 10 (5.4) 1 (0.5) 1 (0.5)
15–24 kg (N = 46) 22 (47.8) 1 (2.2) 22 (47.8) 1 (2.2)
Table 3: Antimalarial treatments for children with uncomplicated malaria presenting to health facilities with artemether-lumefantrine 
in stock – change of practice between 2004 and 2006 surveys in four districts in Zambia
2004 5–9 kg (N = 254) ≥ 10 kg (N = 192)
No (%) 95% CI* No (%) 95% CI*
Artemether-lumefantrine 6 (2.4) 0, 5.7 42 (21.9) 12.4, 31.3
Sulphadoxine-pyrimethamine 183 (72.1) 61.0, 83.1 103 (53.7) 39.7, 67.6
Quinine 9 (3.5) 0.3, 6.8 6 (3.1) 0.4, 5.9
No antimalarial prescribed 56 (22.1) 11.6, 32.5 41 (21.4) 12.7, 30.0
2006 5–9 kg (N = 351) ≥ 10 kg (N = 374)
No (%) 95% CI* No (%) 95% CI*
Artemether-lumefantrine 144 (41.0) 31.5, 50.5 219 (58.6) 50.2, 66.9
Sulphadoxine-pyrimethamine 77 (21.9) 15.4, 28.5 51 (13.6) 7.1, 20.2
Quinine 8 (2.3) 0.1, 4.5 14 (3.7) 0, 7.9
No antimalarial prescribed 122 (34.8) 27.2, 42.3 90 (24.1) 17.4, 30.7
* Confidence intervals adjusted for cluster samplingMalaria Journal 2007, 6:31 http://www.malariajournal.com/content/6/1/31
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with this responsibility [31,32]. Updating revisions to
new treatment recommendations is critical but often a
neglected dynamic component of policy implementation.
The Zambian studies in 2004 and 2006 show that arte-
mether-lumefantrine dosing was largely accurate among
the two dominant weight group categories of 5 to 9 kg and
10 to 14 kg (Table 4), and advice was given on how to take
subsequent doses at home to the majority of caretakers.
These are encouraging findings given the common dosing
and counseling deficiencies reported for sulphadoxine-
pyrimethamine use in Kenya [10]. However, an area of
concern is that approximately one in five febrile children
still left the clinic in both years without any antimalarial
prescribed (Tables 2 and 3). Most of rural Zambia, includ-
ing all our study districts, is located in high malaria risk
areas regarded by national and international guidelines as
meriting treatment of all childhood fevers with antimalar-
ial drugs irrespective of other causes [18-21,33]. However,
closer examination of the patient group that did not
receive any antimalarial treatment revealed a variety of
diagnoses made by the examining health workers. It
appears that health workers were making a differential
diagnosis, that led to a clinical judgment on other possi-
ble causes of the presenting fever and thus not presump-
tively treating all fevers as malaria as recommended in
guidelines and training materials.
Conclusion
The studies reported here provide important information
to measure the operational implementation of new drug
policies. The Zambian experience as an early implementer
of large-scale use of ACT offers valuable lessons for both
further improvements in the national program and also
for other countries in the region. Though improvements
in health facility and health worker readiness and appro-
priate case-management occurred during the initial three
year's experience, major areas of suboptimal performance
still exist – especially in ensuring the effectiveness of the
drug supply and management, improving effective trans-
lation of research into guidelines, and subsequently
guidelines into clinical practice. Furthermore, repeated
evaluation research needs to become a regular part of pro-
gram implementation with consistent financial support
so program and global policies can learn in a timely fash-
ion from the efforts currently underway to mitigate the
mortality and morbidity impacts of the malaria scourge in
Africa.
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